Quarterly ResultMay 11, 2026, 04:11 PM
Oculis Q1 Net Loss Narrows to CHF 28.85M; Key Clinical Trials Advance
AI Summary
Oculis Holding AG reported a net loss of CHF 28.85 million for Q1 2026, an improvement from CHF 33.21 million in Q1 2025, with basic and diluted loss per share narrowing to CHF 0.49. Operating loss increased to CHF 21.73 million, driven by higher general and administrative expenses, partially offset by reduced R&D costs as the OCS-01 DME trials near topline results in June 2026. The company also highlighted significant progress in its clinical pipeline, including a Special Protocol Assessment from the FDA for Privosegtor's PIONEER-1 study.
Key Highlights
- Q1 2026 net loss narrowed to CHF 28.85 million from CHF 33.21 million in Q1 2025.
- Basic and diluted loss per share improved to CHF 0.49 from CHF 0.69 year-over-year.
- Operating loss increased to CHF 21.73 million in Q1 2026 from CHF 19.97 million in Q1 2025.
- Research and development expenses decreased to CHF 14.05 million from CHF 14.77 million.
- General and administrative expenses rose to CHF 7.89 million from CHF 5.49 million.
- Cash and cash equivalents stood at CHF 64.56 million as of March 31, 2026.
- OCS-01 DME DIAMOND trials completed last patient visits in April 2026; topline results expected June 2026.
- Privosegtor PIONEER-1 study received Special Protocol Assessment (SPA) from FDA in May 2026.